Literature DB >> 19450841

Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level.

Stacy Loeb1, H Ballentine Carter, Patrick C Walsh, William B Isaacs, Anna Kettermann, Toshiko Tanaka, Luigi Ferrucci, E Jeffrey Metter.   

Abstract

PURPOSE: Prostate specific antigen is used for prostate cancer screening but its specificity is limited. Specificity might be increased by considering genotype associated prostate specific antigen levels.
MATERIALS AND METHODS: We examined associations between single nucleotide polymorphisms on chromosomes 10 and 19 (previously shown to be associated with prostate specific antigen) with prostate specific antigen and prostate cancer in 505 men from the Baltimore Longitudinal Study of Aging.
RESULTS: In a model with age and date the risk ratio for prostate cancer was 1.18 (95% CI 1.13-1.23) per unit increase in prostate specific antigen. Including the interaction between alleles and prostate specific antigen significantly altered the risk ratio for prostate cancer (Cox proportional hazards p <0.001). Specifically prostate cancer risk per unit increase in prostate specific antigen was significantly different in carriers than in noncarriers of a minor allele (1.28 vs 1.10, respectively, Cox proportional hazards p <0.001), whereas men with a minor allele had a significantly higher risk of prostate cancer at prostate specific antigen levels greater than 6 ng/ml.
CONCLUSIONS: Our data suggest that genotype influences the risk of prostate cancer per unit increase in prostate specific antigen. Prostate cancer risk stratification using prostate specific antigen and genotype could improve prostate specific antigen test performance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450841      PMCID: PMC4642710          DOI: 10.1016/j.juro.2009.02.126

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  A common variant associated with prostate cancer in European and African populations.

Authors:  Laufey T Amundadottir; Patrick Sulem; Julius Gudmundsson; Agnar Helgason; Adam Baker; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Jean-Baptiste Cazier; Jesus Sainz; Margret Jakobsdottir; Jelena Kostic; Droplaug N Magnusdottir; Shyamali Ghosh; Kari Agnarsson; Birgitta Birgisdottir; Louise Le Roux; Adalheidur Olafsdottir; Thorarinn Blondal; Margret Andresdottir; Olafia Svandis Gretarsdottir; Jon T Bergthorsson; Daniel Gudbjartsson; Arnaldur Gylfason; Gudmar Thorleifsson; Andrei Manolescu; Kristleifur Kristjansson; Gudmundur Geirsson; Helgi Isaksson; Julie Douglas; Jan-Erik Johansson; Katarina Bälter; Fredrik Wiklund; James E Montie; Xiaoying Yu; Brian K Suarez; Carole Ober; Kathleen A Cooney; Henrik Gronberg; William J Catalona; Gudmundur V Einarsson; Rosa B Barkardottir; Jeffrey R Gulcher; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2006-05-07       Impact factor: 38.330

2.  Prostate cancer--more information and more questions.

Authors:  Marc Dall'Era; Peter R Carroll
Journal:  J Urol       Date:  2007-05       Impact factor: 7.450

3.  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.

Authors:  Julius Gudmundsson; Patrick Sulem; Valgerdur Steinthorsdottir; Jon T Bergthorsson; Gudmar Thorleifsson; Andrei Manolescu; Thorunn Rafnar; Daniel Gudbjartsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Thorarinn Blondal; Simon N Stacey; Agnar Helgason; Steinunn Gunnarsdottir; Adalheidur Olafsdottir; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Steinunn Thorlacius; Dana Magnusdottir; Gerdur Stefansdottir; Kristleifur Kristjansson; Yu Bagger; Robert L Wilensky; Muredach P Reilly; Andrew D Morris; Charlotte H Kimber; Adebowale Adeyemo; Yuanxiu Chen; Jie Zhou; Wing-Yee So; Peter C Y Tong; Maggie C Y Ng; Torben Hansen; Gitte Andersen; Knut Borch-Johnsen; Torben Jorgensen; Alejandro Tres; Fernando Fuertes; Manuel Ruiz-Echarri; Laura Asin; Berta Saez; Erica van Boven; Siem Klaver; Dorine W Swinkels; Katja K Aben; Theresa Graif; John Cashy; Brian K Suarez; Onco van Vierssen Trip; Michael L Frigge; Carole Ober; Marten H Hofker; Cisca Wijmenga; Claus Christiansen; Daniel J Rader; Colin N A Palmer; Charles Rotimi; Juliana C N Chan; Oluf Pedersen; Gunnar Sigurdsson; Rafn Benediktsson; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; William J Catalona; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

4.  Cumulative association of five genetic variants with prostate cancer.

Authors:  S Lilly Zheng; Jielin Sun; Fredrik Wiklund; Shelly Smith; Pär Stattin; Ge Li; Hans-Olov Adami; Fang-Chi Hsu; Yi Zhu; Katarina Bälter; A Karim Kader; Aubrey R Turner; Wennuan Liu; Eugene R Bleecker; Deborah A Meyers; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Jianfeng Xu; Henrik Grönberg
Journal:  N Engl J Med       Date:  2008-01-16       Impact factor: 91.245

5.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; M Scott Lucia; Phyllis J Goodman; John J Crowley; Howard L Parnes; Charles A Coltman
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

6.  The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.

Authors:  L Beke; M Nuytten; A Van Eynde; M Beullens; M Bollen
Journal:  Oncogene       Date:  2007-01-22       Impact factor: 9.867

7.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

8.  Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.

Authors:  C Sävblom; A Giwercman; J Malm; C Halldén; K Lundin; H Lilja; Y Giwercman
Journal:  Int J Androl       Date:  2008-03-10

9.  Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24.

Authors:  Miia Suuriniemi; Ilir Agalliu; Daniel J Schaid; Bo Johanneson; Shannon K McDonnell; Lori Iwasaki; Janet L Stanford; Elaine A Ostrander
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-04       Impact factor: 4.254

10.  Multiple newly identified loci associated with prostate cancer susceptibility.

Authors:  Rosalind A Eeles; Zsofia Kote-Jarai; Graham G Giles; Ali Amin Al Olama; Michelle Guy; Sarah K Jugurnauth; Shani Mulholland; Daniel A Leongamornlert; Stephen M Edwards; Jonathan Morrison; Helen I Field; Melissa C Southey; Gianluca Severi; Jenny L Donovan; Freddie C Hamdy; David P Dearnaley; Kenneth R Muir; Charmaine Smith; Melisa Bagnato; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Beatrice N Gehr-Swain; Rosemary A Wilkinson; Angie Cox; Sarah Lewis; Paul M Brown; Sameer G Jhavar; Malgorzata Tymrakiewicz; Artitaya Lophatananon; Sarah L Bryant; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Cyril Fisher; Charles Jamieson; Colin S Cooper; Dallas R English; John L Hopper; David E Neal; Douglas F Easton
Journal:  Nat Genet       Date:  2008-02-10       Impact factor: 38.330

  10 in total
  12 in total

1.  Genetics: Prostate cancer risk stratification by genotype and PSA.

Authors:  Jonathan L Wright; Daniel W Lin
Journal:  Nat Rev Urol       Date:  2009-12       Impact factor: 14.432

2.  Prostate cancer: improving PSA testing by adjusting for genetic background.

Authors:  Peter T Scardino
Journal:  Nat Rev Urol       Date:  2013-02-19       Impact factor: 14.432

3.  Do environmental factors modify the genetic risk of prostate cancer?

Authors:  Stacy Loeb; Sarah B Peskoe; Corinne E Joshu; Wen-Yi Huang; Richard B Hayes; H Ballentine Carter; William B Isaacs; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-23       Impact factor: 4.254

Review 4.  A genetic-based approach to personalized prostate cancer screening and treatment.

Authors:  Brian T Helfand; William J Catalona; Jianfeng Xu
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

5.  Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies.

Authors:  Brian T Helfand; Stacy Loeb; Qiaoyan Hu; Phillip R Cooper; Kimberly A Roehl; Barry B McGuire; Nikola A Baumann; William J Catalona
Journal:  J Urol       Date:  2013-02-27       Impact factor: 7.450

6.  Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.

Authors:  Bao-Li Chang; Lucinda Hughes; David Y T Chen; Laura Gross; Karen Ruth; Veda N Giri
Journal:  BJU Int       Date:  2013-08-13       Impact factor: 5.588

7.  Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Nicolas Wentzensen; Amanda Black; Kevin Jacobs; Hannah P Yang; Christine D Berg; Neil Caporaso; Ulrike Peters; Lawrence Ragard; Saundra S Buys; Stephen Chanock; Patricia Hartge
Journal:  PLoS One       Date:  2011-07-07       Impact factor: 3.240

8.  Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.

Authors:  Rebecca Gilbert; Richard M Martin; David M Evans; Kate Tilling; George Davey Smith; John P Kemp; J Athene Lane; Freddie C Hamdy; David E Neal; Jenny L Donovan; Chris Metcalfe
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

Review 9.  The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making.

Authors:  Thomas Van den Broeck; Steven Joniau; Liesbeth Clinckemalie; Christine Helsen; Stefan Prekovic; Lien Spans; Lorenzo Tosco; Hendrik Van Poppel; Frank Claessens
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

10.  Replication study of 34 common SNPs associated with prostate cancer in the Romanian population.

Authors:  Viorel Jinga; Irma Eva Csiki; Andrei Manolescu; Paul Iordache; Ioan Nicolae Mates; Daniel Radavoi; Stefan Rascu; Daniel Badescu; Paula Badea; Dana Mates
Journal:  J Cell Mol Med       Date:  2016-01-15       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.